Characteristics | ||
---|---|---|
Age (years) | 59.9 ± 7.9 | |
Gender | Female | 12 (40.0%) |
Male | 18 (60.0%) | |
HCV | 13 (43.3%) | |
HCV + Alcohol | 7 (23.3%) | |
Liver disease etiology | Alcohol | 4 (13.3%) |
HBV | 1 (3.3%) | |
Other | 5 (16.7%) | |
Child-Pugh class | A | 10 (33.3%) |
B | 20 (66.7%) | |
BCLC stage | A | 17 (56.7%) |
B | 13 (43.3%) | |
Baseline tumor size (mm) | 20.3 ± 10.1 | |
Lobar | 16 (34.8%) | |
Treatment selectivity | Segmental | 22 (47.8%) |
Sub-segmental | 8 (17.4%) | |
Baseline Lipiodol uptake (HU) | 328.3 ± 185.2 | |
Lipiodol uptake at final evaluation (HU) | 205.0 ± 219.5 | |
Washout (HU) | 136.9 ± 127.6 | |
Follow-up time (months) | 5.6 ± 6.2 | |
Tumor recurrence | Yes | 19 (41.3%) |
No | 27 (58.7%) |
Predicting factor | Univariate model | Multivariate model Variables with a p value less than 0.200 were entered in the multivariate model. | ||
---|---|---|---|---|
Hazard ratio (CI) | Hazard ratio (CI) | |||
Lesion size (mm) | 0.70 (0.24-2.09) | 0.527 | - | - |
Treatment selectivity (Segmental or subsegmental vs. lobar) | 0.19 (0.07–0.51) | 0.001 | 3.05 (0.62–15.05) | 0.171 |
Baseline Lipiodol uptake (HU) | 0.37 (0.19–0.70) | 0.002 | 0.002 (0.0–0.087) | 0.001 |
Presence of Lipiodol washout | NA Not calculated because no tumors without Lipiodol washout recurred while 65.5% (19/29) of the tumors with Lipiodol washout recurred. | NA | - | - |
Washout rate (HU/month) | 3.37 (1.78–6.36) | < 0.0001 | 149.03 (11.20–1983.54) | < 0.0001 |